1. Home
  2. MNTS vs OGEN Comparison

MNTS vs OGEN Comparison

Compare MNTS & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Momentus Inc.

MNTS

Momentus Inc.

HOLD

Current Price

$7.88

Market Cap

20.3M

Sector

Industrials

ML Signal

HOLD

Logo Oragenics Inc.

OGEN

Oragenics Inc.

HOLD

Current Price

$0.82

Market Cap

3.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MNTS
OGEN
Founded
2017
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.3M
3.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MNTS
OGEN
Price
$7.88
$0.82
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
559.9K
88.5K
Earning Date
11-20-2025
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,032,000.00
N/A
Revenue This Year
$286.00
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.35
$0.82
52 Week High
$183.86
$18.90

Technical Indicators

Market Signals
Indicator
MNTS
OGEN
Relative Strength Index (RSI) 92.76 32.85
Support Level $0.44 $0.85
Resistance Level $1.02 $0.99
Average True Range (ATR) 0.29 0.06
MACD 0.46 0.00
Stochastic Oscillator 79.48 2.38

Price Performance

Historical Comparison
MNTS
OGEN

About MNTS Momentus Inc.

Momentus Inc offers in-space infrastructure services by building transfer and service vehicles that carry satellites and hosted payloads between orbits in space. It is a provider of three critical functions, in the new space economy: Space Transportation, Satellite as a Service, and In-Orbit Servicing.

About OGEN Oragenics Inc.

Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.

Share on Social Networks: